Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia

Mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors have shown single-agent activity in relapsed/refractory acute myeloid leukemia (AML), even though most patients eventually relapse. We evaluated the efficacy and molecular mechanism of the combination treatment with azacitidine, which is currently...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Chaturvedi, Anuhar, Gupta, Charu, Gabdoulline, Razif, Borchert, Nora M., Goparaju, Ramya, Kaulfuss, Stefan, Gorlich, Kerstin, Schottmann, Renate, Othman, Basem, Welzenbach, Julia, Panknin, Olaf, Wagner, Markus, Geffers, Robert, Ganser, Arnold, Thol, Felicitas, Jeffers, Michael, Haegebarth, Andrea, Heuser, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Fondazione Ferrata Storti 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7849562/
https://ncbi.nlm.nih.gov/pubmed/32241846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.236992
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados